Live birth rates are similar between fresh and frozen embryo transfers for normal responders. Freeze-all is clearly better for PMOS patients, high responders, and anyone doing PGT-A. The trade-offs: FET adds cost and time but reduces OHSS risk. Medicated FET cycles carry a modest pre-eclampsia risk that natural/modified FET protocols may mitigate.
Key Takeaways
60-70% of US IVF cycles now use frozen embryo transfer — freeze-all has become the default at many clinics
Live birth rates are comparable between fresh and frozen for normal responders — but PMOS patients and high responders clearly benefit from freeze-all
FET virtually eliminates OHSS risk and enables PGT-A testing — the main trade-offs are cost ($3K-$6K more) and 1-3 month delay
Medicated FET carries a modest pre-eclampsia risk — natural or modified FET protocols may reduce this by preserving corpus luteum function
The Freeze-All Revolution
A decade ago, most IVF cycles ended with a "fresh" embryo transfer — putting an embryo back into the uterus during the same cycle as egg retrieval. Today, "freeze-all" strategies (freezing all embryos for transfer in a subsequent cycle) have become the default at many clinics. The shift is backed by growing evidence and changing clinical priorities.
Fresh vs Frozen: What the Evidence Shows
| Factor | Fresh Transfer | Frozen Embryo Transfer (FET) |
|---|---|---|
| Timing | 5–6 days after egg retrieval | 1–3 months after retrieval (separate cycle) |
| Endometrial environment | Post-stimulation — supraphysiologic hormones | Natural or medicated — more physiologic |
| OHSS risk | Higher (eggs + embryo in same cycle) | Eliminated (trigger cycle separated from transfer) |
| Live birth rate (general) | 40–50% | 40–55% |
| Live birth rate (PMOS) | Lower (OHSS risk, poor lining) | Higher — PMOS patients clearly benefit from FET |
| PGT-A compatibility | Difficult (results may not return in time) | Ideal — results available before transfer |
| Ectopic pregnancy risk | Slightly higher | Slightly lower |
| Pre-eclampsia risk | Baseline | Modestly elevated in medicated FET cycles |
| Cost | Included in IVF cycle | Additional $3,000–$6,000 for FET cycle |
| Time to pregnancy | Faster (if successful) | Delayed by 1–3 months |
When Freeze-All Is Clearly Better
- PMOS patients: High OHSS risk + often suboptimal endometrium during stimulation. FET dramatically reduces OHSS and improves implantation rates in this population.
- PGT-A testing: Genetic results take 7–14 days (sometimes longer). Freezing allows transfer of a confirmed euploid embryo.
- High responders (>15 eggs): Supraphysiologic estrogen levels can impair endometrial receptivity and increase OHSS risk.
- Progesterone elevation at trigger: Elevated progesterone before retrieval can advance the endometrium prematurely, reducing implantation rates. FET avoids this entirely.
- Fertility preservation: Egg/embryo banking inherently involves freezing.
When Fresh Transfer May Be Preferred
- Normal responders without PGT-A: For patients with 5–15 eggs and normal progesterone at trigger, fresh transfer avoids the added cost, time, and medication of a FET cycle.
- Poor responders: Patients with very few embryos (1–2) may prefer to avoid the theoretical risk of freeze/thaw damage, though modern vitrification makes this risk minimal (<2% loss).
- Time pressure: Patients with time constraints (age, scheduling) may prefer the faster path to pregnancy.
- Lower responders where endometrium looks good: If stimulation produced a moderate response and the lining is ideal at trigger, fresh transfer is reasonable.
A 2018 RCT in NEJM (ESHRE freeze-all trial) found no significant difference in live birth rates between fresh and frozen transfer in normal responders. However, OHSS rates were significantly lower in the freeze-all group. A separate 2023 meta-analysis confirmed that PMOS patients and high responders consistently benefit from freeze-all strategies.
The Pre-Eclampsia Question
One concern with FET — particularly medicated FET cycles — is a modestly elevated risk of pre-eclampsia. The theory: in a medicated FET, there's no corpus luteum (the progesterone-producing structure that normally forms after ovulation). The corpus luteum produces vasoactive substances that may protect against hypertensive disorders of pregnancy.
💡 If pre-eclampsia risk concerns you, discuss natural or modified-natural FET protocols with your RE. These involve ovulation (creating a corpus luteum) before transfer, potentially reducing the hypertensive risk while maintaining FET benefits. Not all clinics offer natural FET cycles.
FET Protocols: Medicated vs Natural
| Factor | Medicated FET | Natural FET | Modified Natural FET |
|---|---|---|---|
| Ovulation required | No — lining built with estrogen | Yes — relies on natural ovulation | Yes — with trigger shot for timing |
| Corpus luteum | Absent | Present | Present |
| Scheduling flexibility | Highly flexible | Limited — follows natural cycle | Moderate |
| Monitoring visits | 2–4 | 4–6 | 3–5 |
| Medications | Estrogen + progesterone | Progesterone only (sometimes) | Trigger + progesterone |
| Cancel rate | Low | Higher (if ovulation doesn't occur) | Moderate |
| Pre-eclampsia risk | Slightly elevated | Baseline | Baseline |
For supplements that support endometrial lining quality before transfer, visit Vitamin D & Fertility on LifeFertile. For managing the emotional wait between retrieval and transfer, FertileStart has support resources.